2005
DOI: 10.1002/jmv.20322
|View full text |Cite
|
Sign up to set email alerts
|

Profiles of HCV core protein and viremia in chronic Hepatitis C: possible protective role of core antigen in liver damage

Abstract: The relation between HCV core antigen and HCV RNA has been confirmed in patients with chronic hepatitis C and a parallel behavior of the two markers has been described in early kinetics analysis during antiviral therapy. Variations of the core antigen to HCV RNA ratio have been reported in individual patients and the existence of nucleocapsid particles, not always associated with viral genomes, have been described. To assess the characteristics of HCV core antigen reactivity in relation to viremia in patients … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
11
0

Year Published

2005
2005
2013
2013

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(12 citation statements)
references
References 22 publications
1
11
0
Order By: Relevance
“…22 Some evidence suggests that the ratio of HCV RNA to core antigen has prognostic value. 22,30 For the comparison of pre-LT samples to all post-LT samples, there was a nonsignificant trend toward a decrease in the ratio of HCV RNA to core antigen (14,000 vs. 8,000; P ϭ .34). The difference in the ratio was statistically sig- Fig.…”
Section: Early Viral Kineticsmentioning
confidence: 98%
“…22 Some evidence suggests that the ratio of HCV RNA to core antigen has prognostic value. 22,30 For the comparison of pre-LT samples to all post-LT samples, there was a nonsignificant trend toward a decrease in the ratio of HCV RNA to core antigen (14,000 vs. 8,000; P ϭ .34). The difference in the ratio was statistically sig- Fig.…”
Section: Early Viral Kineticsmentioning
confidence: 98%
“…It has been proposed that infectious particles are assembled when genomic RNA-containing core particles bud through the endoplasmic reticulum (ER) membrane (47), acquiring the viral envelope and surface glycoproteins (14,15,48). However, it is currently unknown how the viral particles are transported from the ER through the secretory pathway.In infected individuals, HCV particles circulate as low-density lipoprotein (LDL)-virus complexes (3) characterized by very-low-to-low buoyant densities (from Ͻ1.03 to 1.25 g/ml), depending on the stage of the infection at which the sample is obtained (12,46). These LDL-virus particles are rich in triglycerides and contain HCV RNA, core protein, and apolipoproteins B and E (apoB and apoE) (3), which are components of the beta-lipoproteins (very-low-density lipoproteins [VLDL] and LDL) (11).…”
mentioning
confidence: 99%
“…In infected individuals, HCV particles circulate as low-density lipoprotein (LDL)-virus complexes (3) characterized by very-low-to-low buoyant densities (from Ͻ1.03 to 1.25 g/ml), depending on the stage of the infection at which the sample is obtained (12,46). These LDL-virus particles are rich in triglycerides and contain HCV RNA, core protein, and apolipoproteins B and E (apoB and apoE) (3), which are components of the beta-lipoproteins (very-low-density lipoproteins [VLDL] and LDL) (11).…”
mentioning
confidence: 99%
“…HCV RNA displays various density profiles, depending on the stage of the infection at which the sample is obtained (11,58). The differences in densities and infectivities have been attributed to the presence of host lipoproteins and antibodies bound to the circulating viral particles (24,58).…”
mentioning
confidence: 99%